Predict Effect of Response and Survival of Polymorphisms of XPD, XPA, XRCC1 and GSTP1 in Patients with Advanced Gastric Cancer Treated with Oxaliplatin Based Chemotherapy
|Keywords||Gene polymorphism Advanced gastric cancer Oxaliplatin Chemotherapy|
Objective: This study investigated the peripheral blood of patients with advanced gastric cancer XPD Lys751Gln, XPA A23G of XRCC1 of Arg399Gln, GSTPlIle105Val gene polymorphisms with oxaliplatin-based chemotherapy efficacy and lifetime of the relationship. Methods: 110 cases diagnosed with advanced gastric cancer and accept the peripheral blood of patients with oxaliplatin-based chemotherapy, the use of the method of analysis and gene sequencing of the PCR-PFLP all patients with XPD Lys751Gln, XPA A23G of XRCC1 of Arg399Gln GSTP1Ile105Val gene polymorphism. Evaluate the efficacy of 2 chemotherapy cycles according to RECIST criteria and statistical chemotherapy, progression-free survival (mPFS) and overall survival period (MST). Analyze the relationship of the different genotypes of each gene and the efficacy of chemotherapy and survival. Results: 1,110 patients with advanced gastric cancer patients with chemotherapy effective rate of 49.1%, mPFS128 days, MST 308 days. XPD Lys751Gln, XPA A23G of Arg399Gln of XRCC1 GSTPllle105Val gene genetic subtype distribution are in line with the Hardy-Weinberg law. Chemotherapy efficiency and XRCC1 of Arg399Gln the GSTPlIle105Val gene polymorphism has nothing to do with the XPD Lys751Gln, XPA A23G gene polymorphism. XRCC1 Arg399Gln Arg / Arg Arg / Gln Gln / Gln type efficient statistical difference (62.1% VS 27.9%, X2 = 12.201, P lt; 0.001); of GSTP1 Il105Val Ile / Ile and Ile / Val Val / Val compared to an efficient statistical difference (35.7% vs. 71.2%, X2 = 13.052, P lt; 0.001). 4, no disease progression-free survival (mPFS) gene polymorphisms XRCC1 Arg399Gln, GSTPlIle105Val has nothing to do with the XPD Lys751Gln, XPA A23G gene polymorphism. XRCC1 of Arg399Gln Arg / Arg, Arg / Gln Gln / Gln type, mPFS a statistically significant difference (VS 84 days in 140 days, X2 = 13.801, P lt; 0.001); of GSTP1 Ile105Val Ile / Ile and Ile / Val Val / Val compared mPFS significant statistical difference VS 150 days (90 days, X2 = 18.579, P lt; 0.001). 5, the overall survival time (MST) of Arg399Gln of XRCC1, GSTP1Ile105Val genetic polymorphisms, and XPD Lys751Gln, XPA A23G gene polymorphism unrelated. XRCC1 Arg399Gln Arg / Arg Arg / Gln Gln / Gln type, MST there is a statistically significant difference (330 days VS.210 days, X2 = 21.249, P lt; 0.001); of GSTP1 Ile105Val Ile / Ile type Ile / Val Val / Val compared, MST, a statistically significant difference (228 days VS 356 days, X2 = 21.555, P lt; 0.001). 6 gene polymorphism joint analysis found 0 risk gene group, a risk gene group, two risk gene set of the three groups of patients mPFS, there are significant with difference X2 = 28.508, P lt; 0.001; and the three groups of patients carried two the two comparison: the 0 risk genome and compared to a risk genomic X2 = 15.967, P lt; 0.001, both with significant difference; a 0 risk genome and compared to two risk genomic X2 = 25.076, P lt; 0.001, both statistically differences; a risk genome and two risk genomic X2 = 3.741, P = 0.053, no statistically significant difference between the two. Correction using Cox hazard regression model, the 0 risk genotype as a reference, can be found mPFS with a (P lt; 0.001) or 2 (P = 0.0037) risk genes. 7,3 group of patients MST significant difference X2 = 40.311, P lt; 0.001; and the three groups were conducted pairwise comparisons: 0 risk gene group a risk gene group, X2 = 16.142, P lt; 0.001; the 0 risk gene groups, and the two risk gene group X2 = 40.046, P lt; 0.001; 1 risk gene group and two risk gene groups compared, X2 = 9.150, P = 0.002, both have have statistically significant difference. Correction and Cox hazard regression model, 0 risk genotypes as a reference, and can be found in the MST shorter with a (P lt; 0.001) or 2 (P = 0.001) risk genes. Conclusion: of XRCC1 of Arg399Gln, GSTPlIle105Val gene polymorphism with advanced gastric cancer patients with oxaliplatin-based chemotherapy chemotherapy efficiency and survival-related gene polymorphisms joint detection and a better prediction of survival.